Anuncio • Jan 22

Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-Term Therapeutic Effects of PoNS Therapy on Gait Deficit Improvement in Multiple Sclerosis from the PoNS Therapeutic Experience Program Study

Helius Medical Technologies, Inc. announced positive results from the PoNS Therapeutic Experience Program, or PoNSTEP, study for people with multiple sclerosis (MS). “The results from this study validate existing evidence of the efficacy of PoNS across clinical data and real-world utilization of the therapy by demonstrating durability of effect as further evidence of its long-term therapeutic benefits,” stated Antonella Favit-Van Pelt, M.D., Ph.D., Helius’ Chief Medical Officer. “The PoNSTEP study marks an important stepstone in further understanding the role of neuromodulation and, consequently, neuroplasticity in gait function rehabilitation. PoNS Therapy’s neuromodulation effect on brain mechanisms of motor control is likely to enhance neuroplasticity and contribute to maintain PoNS therapeutic effect on gait deficit in people with MS.” The recently completed study, provides the first clinical evidence of a positive relationship between adherence to using the PoNS device with targeted physical exercise (PoNS Therapy) and improvement of gait deficit, along with establishing the long-term therapeutic effect of PoNS Therapy at six months post-treatment in people with MS. This observation is in line with maintenance of effect’s evidence from other clinical trials in people with balance deficits due to traumatic brain injury. The study involved 43 patients with gait deficit due to mild-to-moderate MS, who received 14 weeks of physical rehabilitation with PoNS Therapy. The therapy included 2 weeks in the clinic (Phase 1) and 12 weeks at home (Phase 2), followed by a 6-month post-treatment observation (Phase 3). Of the 41 patients who started, 38 completed the study, and 29 were evaluated at 6 months. Patients with a 30% or greater decline in functional improvement were eligible for an additional 12 weeks of therapy. The primary outcome measure was the DGI, with changes evaluated using statistical tests and correlation analyses to assess adherence and DGI improvements. PoNSTEP Results There were statistically significant findings in DGI during Phase 1 and Phase 2 among the 38 subjects who completed the treatment protocol for a total mean improvement of 5.00 (4.1 to 5.9, p<0.001) at week 14. In Phase 2, average therapy adherence 71% and gait improvement was linearly associated with adherence (r=0.345; p=0.034), while, in Phase 1 adherence, was 89.5% and, consequently, not associated with improvement. In addition to mean 2.5 points improvement in DGI achieved in Phase 1, Phase 2, participants with =85% adherence improved mean 3.7 points [1.8 SD]; those with <85% adherence improved mean 2.0 points [1.8 SD], and the difference was statistically significant [p=.0.008]. 28 of 41 (70.7%) participants who completed the 14-wk therapy were reassessed at 6-months and only 1 of 28 showed = 30% decline in DGI (95% exact binomial CI: 0.09% to 18.4%). Mean decline (%) in DGI was -4.1 (95% CI -9.4% to 1.1%; range -35.7% to 25.0%) with the 95% CI’s lower bound showing statistically reliable evidence that the true mean decline was no more than -9.4% (p=0.12). About PoNS Therapeutic Experience Program (PoNSTEP) The Therapeutic Experience Program (“TEP”) is a Helius-sponsored, open label observational, interventional multi-center outcome research study designed to assess adherence to on-label PoNS therapy for improvement in gait deficits for patients with multiple sclerosis (“MS”) in a real-world clinical setting. The study aims to understand better the relationship between adherence to on label (100-120 minute per day) PoNS Therapy, which combines the PoNS device with physical therapy, and the therapeutic outcome on gait deficit improvement over 14 weeks of study treatment, as measured by changes in the Dynamic Gait Index (DGI) scores. PoNS therapy is applied in a supervised clinical setting for the first two weeks (Phase 1) and, independently, at home for the remaining 12 weeks (Phase 2). The study also includes a six month no-treatment follow-up phase aimed at establishing durability of therapeutic effect (Phase 3). The primary endpoint of the study is maintenance of gait improvement from the end of supervised therapy (Phase 1) to the end of unsupervised therapy (Phase 2) in relation to the subject’s adherence to PoNS therapy. The secondary endpoints are, among others, maintenance of improvement of gait and balance deficit over 6-m timeframe and clinical global impression of change. The study was performed at six Centers of Excellence across the United States, including Neurology Center of New England in Foxboro (MA), the Shepherd Center in Atlanta (GE), Montefiore Medical Center (“Montefiore”) in NY (NY), Oregon Health & Science University (“OHSU”) in Portland (OR), MGH Institute of Health Professions in Boston (MA), NYU Langone Health in NY (NY), and recruited 43 MS participants with gait deficit.

Seeking Alpha • Aug 23

Helius Medical Technologies: A Net-Net Meme Stock In The Making

A curious $14.5m microcap that $100m in value has transacted through in just 15 trading sessions. A recent equity raise increased cash position by $16.4m in August. The company is currently net-net trading below net current asset value. P/B is 0.69x. Shorts are likely to be forced to cover in the next two months given high cost to borrow rate of 558% currently, second highest amongst US stocks. With Reddit retail investors piling in and billionaire hedge funds involved, I think we have a meme stock in the making poised for a volatile short squeeze. Helius Medical Technologies (HSDT) is a tiny microcap with a $14.51m market capitalization that $100m in volume has transacted through in the past month. Incredibly irregular trading behavior underlies the stock price while the business itself appears poised for a turnaround. After a recent equity raise resulting in $16.4m cash and no debt the company is trading at a P/B of 0.69x and is currently a net-net situation. Cash burn from the last two quarters suggests a $4.15m quarterly burn rate with the company. Market launch of their Portable Neuromodulation Stimulator or PoNS device in the US was in Q1 which builds on their previous launch in Canada in 2019. They are first to market with a novel device leveraging insights in neuroplasticity to improve gait deficit for those suffering with multiple sclerosis. Cash on hand should fund commercialization efforts through the year. Structural elements related to cost-to-borrow fees suggest a short squeeze is very likely in the coming two months. With underlying fundamentals seeming to improve at the company, the stock trading below book value, and building retail interest in the name it’s possible a short squeeze could be quite abrupt and over 100%. Helius Medical Technologies The Company From their website we can see a quick overview of the company in their words: Helius Medical Technologies, Inc., (“Helius”), is a neurotech company in the medical device industry, focused on neurological wellness. Helius’ origin stems from the early 1990s, and the pioneering work in neuroplasticity at the Tactile Communication and Neurorehabilitation Laboratory, (“TCNL”), at the University of Wisconsin-Madison. This work led to the development of the investigational Portable Neuromodulation Stimulator (PoNSTM), delivering neurostimulation via the tongue which has been shown in clinical studies to improve the effectiveness of physical exercises in people with neurological symptoms from disease or trauma such as mild-to-moderate traumatic brain injury. They went public in 2014 via a reverse merger with Canadian company NeruoHabiliation, then listed on the Toronto Stock Exchange (TSX) in 2016, and finally listed on the NASDAQ in 2018. Their lead PoNS device was approved in Canada in late 2018, FDA authorized in March 2021, and also authorized in Australia in November 2021. Commercialization efforts have been ongoing in Canada while efforts in the US began just this year. Results thus far have lagged hoped for results per management’s commentary. Turning to our Canadian activities. Since 2019, PoNS has been authorized for sale in Canada for chronic balance deficit due to mild-to-moderate traumatic brain injury and subsequently for the treatment of gait deficit due to mild-to-moderate symptoms from MS. We now have 41 authorized PoNS clinics in Canada, up from 37 at the end of 2021. In addition, we currently have small trial programs with a few insurance carriers in Canada evaluating the benefit of PoNS therapy which we hope will lead to coverage by some or all of those carriers in the near future. Having said that, while we have gained valuable data from our patients in Canada, some of which we've used to achieve FDA authorization in the U.S., our sales have not reached the levels we have targeted. We are currently evaluating additional measures and alternatives to achieve greater market adoption in Canada. Revenue for the quarter was reported at $119k which is up 68% YoY though with operating expenses at $3.5m there’s a long way to climb to profitability. We can note the pricing data management broke out in the quarterly call as well: “The established U.S. list price for PoNS device is $25,700 comprised of a onetime cost of $17,800 for the controller and $7,900 for the mouthpiece.” From this pricing it implies that they sold four devices in the quarter. That leaves a lot of potential runway for the company as they develop their commercialization efforts. It also may suggest that they are struggling to sell their product especially in light of commentary regarding Canada above. Management is working to expand insurance coverage of their device while also building expertise in physical therapists to actually use it. Their expectation is that revenue will grow sequentially over the quarters as their commercialization efforts start to drive sales. Management has also announced a telehealth, e-commerce, online pharmacy initiative slated for later this year. Through this they are building a direct-to-consumer channel via ponstherapy.com. The strategy is described here: Another hurdle to PoNS use will be lessened when we roll out our telehealth, e-commerce, online pharmacy initiative later this year. ponstherapy.com is an increasingly robust site but we expect the direct-to-consumer e-platform to be a game changer for physicians and patients. Once live, the platform will be immediately available in all 50 states and will include a network of fully licensed providers with e-prescribing capabilities. Currently, it could take a patient several weeks to set up an appointment with their neurologist or primary care physician. Through this site, patients will have the ability to match with practitioners and make appointments online, shrinking the 4-week window to as low of 24 hours. In addition, the online store will give patients the option to have the PoNS device delivered directly to their door. This should provide another vehicle through which the company can generate revenue. I think it’s additionally strategic given it provides the company a digital platform which can be leveraged beyond the single device down the line. All in all, the company is poised to expand their commercialization efforts in the coming quarters and with cash on hand expected to fund them throughout the year it’s merely a question of how much revenue they will generate moving forward, if any. Helius Medical Technologies Financials Let’s look at the balance sheet first. This is from their latest 10-Q filed on August 15th. HSDT 10-Q We need to make some immediate adjustments due to their $18m stock price offering from August 5th. Net proceeds were $16.4m which we’d add to the asset side of the equation bringing total equity value to $20.902m. With the current market cap of $14.5m and net current asset value of $19.42m the company is in a net-net situation. A five quarter average cash burn comes in at $3.72m. With current cash at $19.673m that would imply 5 more quarters of cash on hand assuming no revenue growth. Meme Stock Potential: The Anatomy of A Short Squeeze With a bit of context laid about the company, let’s shift gears a bit and talk about why this is potentially a meme stock in the making. Cost to borrow is a metric which tells potential short sellers what the cost annually is to short a particular stock. This article highlights that “The typical fee for a stock loan is 0.30% per annum. In case of short supply, when many investors are going short on a stock, the fee may go up to 20-30% per annum.” Compare that with HSDT’s current cost to borrow fee which is 558.1% and according to iBorrowDesk is the second most expensive in the US currently. iBorrowDesk Current fee rates compare to the cost to borrow fee being around 18-20% most of last year for HSDT. iBorrowDesk August 9th is when the fees jumped – the day after they closed on their $18m public offering. The offering brought $16.4m in cash to fund ongoing operations while they attempt to ramp up revenue. It also increased shares outstanding from ~4m to 28.179m with an additional 36m warrants outstanding exercisable at $0.75. With the cost to borrow at 558% that implies a very steep return hurdle for those short the stock. What it means is that for those with a short position to return a profit in the next year the stock would need to go to zero. The actual cost to borrow is charged daily and given going to zero is only 100% upside we can gauge that not only does the company need to go to zero to be a profitable short position, it needs to do so before the next three months to be profitable. Annualized cost to borrow 558% HSDT goes to 0 implied return 100% Months until HSDT goes to 0 1 2 3 4 5 Annualized Return Implied 1200.00% 600.00% 400.00% 300.00% 240.00% Is the stock price likely to go to zero in the next three months? From the looks of it, not at all. Instead we can observe the company just raised $16.4m in cash. Quarterly cash burn was $3.7m in Q2 and $4.6m in Q3 so it’d take something beyond the ordinary to cause an impact here. Meanwhile on the other side of this trade you’ve got the meme crowd looking to send this thing through the roof. Let’s consider some data here. Three days ago HSDT was posted in the Reddit r/SqueezePlays. Reddit The thesis is basically that given the low current valuation of the company coupled with a first to market device with no competitors, the cost-to-borrow could drive a short squeeze. And with low float retail investors could themselves cause this to happen. These types of posts are as much a call to action as they are a due diligence note. The action to many was clear: buy and hold. From a review of the comments I calculated around 32 new investors with around 70,900 shares bought. While admittedly not a huge amount of shares, I do think it’s a data point in reference to building retail momentum. Another data point is HSDT’s popularity on investing app Webull rated at number 22 overall on the app on August 20th. Chart of HSDT popularity in Webull Additionally we can see a huge uptick in message volume on HSDT’s StockTwits page in August. HSDT StockTwits message volume chart The sentiment has been overwhelmingly positive. HSDT StockTwits message sentiment chart Yet if we take a look at the volume overall it seems clear this isn’t just retail moving this. Something is though. Consider that since the beginning of August 141.989m shares have exchanged hands – meaning the entire share count has been traded over five times in just fifteen trading sessions. Average volume has been 9.46m shares per day or 34% of shares outstanding. Of note is that volume jumped significantly in August and prior to that five month average daily volume was only 615k shares or around 14% of shares outstanding during that time. The average opening price during this month was $0.71 which given the total 141.989m shares that have traded implies $100m has transacted through this $14m market cap stock. The stock started the month at $0.83, saw highs of $2.76, and is now trading for around $0.51. What does all of this mean? Well I note that the volume spike seems to have started on August 2nd with 3.43m shares trading, above the 869k fifty day average volume. This was just two days before they filed for their $18m public offering. The day before the filing 40m shares traded hands. The day after the filing another 30m traded hands. HSDT one month volume chart from TD Ameritrade What’s surprising about these volume numbers is that this is before the additional 24m shares from the offering hit the market. The filing itself references that as of June 30th there were only 4.195m shares outstanding. This suggests that volume combined the day before and after the filing saw the total share outstanding change hands over 16x in just two trading days. It wasn’t retail that seemingly knew about news of the stock offering pricing and trading around it. Someone did though. Whoever knew about the stock offering pricing news could have also done some math to evaluate what the cost-to-borrow post offering would be so this trading strategy is likely multi-pronged. The first prong of the strategy I’d say was trading around the filing itself back on August 4th. The second prong of the strategy is related to the potential short squeeze and is supported by a company with an improving fundamental runway making this a long term trading vehicle. All of this suggests to me that some group of folks with insider knowledge are using the stock price as a trading vehicle right now. Given the structural elements of the high cost-to-borrow rate and improving fundamentals in the business a short squeeze seems imminent – one that this group likely anticipated. It’s also possible that retail investors are being intentionally digitally mobilized through things like Reddit, Stocktwits, and Webull creating a compounding effect and meme stock potential which ultimately supports downside risk for this possible group. So my assumptions so far are: Someone or group had insider knowledge of stock price offering inclusive of date and terms. I extrapolate this from the surge of volume before and after the date of the filing itself. Trading Opportunity #1 If we assume the above insider knowledge someone would also have been able to gauge the cost to borrow post offering. For reference, the cost to borrow jumped from around 50-60% before the offering to 603% immediately after. With the company just raising capital and their product hitting the markets, this cost to borrow is untenable so shorts will be forced to cover. Trading Opportunity #2 Optionality: weaponize retail army for meme stock potential to support downside. Someone could have sketched this strategy out with insider knowledge. I’m not implying that there is any particular wrongdoing that has happened in terms of stock price manipulation – to that end it’s entirely possible but also unclear to me. I’m also not suggesting that insiders as in staff or executives themselves are the ones driving this. What I am trying to do is develop a hypothesis which accounts for the huge jump in volume that HSDT has witnessed this past month which is truly beyond normal. Given what I’m seeing it seems to me that someone knew this was coming and has taken steps to ensure there are structural supports in place for their trading context. And in my opinion it’s poised to work. Again, structurally speaking shorts will be looking to cover unless they believe the stock price is going to zero within two months. It would be a shocking turnaround in news for this to materialize so even for those that maintain a short thesis for the company over the long term (>1 year) the economics are going to force them to cover. Coupled with what seems to be building retail momentum the short squeeze might be sharp. For reference, on August 2nd the stock closed at $0.64 only to open on August 3rd at $2.00 and close at $1.58, jumps of 212% and 147% respectively. Since then there’s been building discussion on StockTwits and Reddit regarding the name which likely means in a squeeze scenario there will be more holding through it making it harder for shorts to cover then earlier this month.

Puntuación del snowflake
Valoración	1/6
Crecimiento futuro	3/6
Rendimiento pasado	0/6
Salud financiera	4/6
Dividendos	0/6

Precios históricos de las acciones
Precio actual de la acción	US$2.22
Máximo en las últimas 52 semanas	US$25.50
Mínimo de 52 semanas	US$1.19
Beta	1.07
Cambio en 1 mes	30.59%
Variación en 3 meses	36.20%
Cambio de 1 año	-87.85%
Variación en 3 años	-99.90%
Variación en 5 años	-99.90%
Variación desde la OPV	-99.90%

	HSDT	US Medical Equipment	Mercado US
7D	-0.9%	-5.5%	-0.9%
1Y	-87.8%	-18.1%	13.9%

HSDT volatility
HSDT Average Weekly Movement	12.5%
Medical Equipment Industry Average Movement	8.2%
Market Average Movement	6.9%
10% most volatile stocks in US Market	15.3%
10% least volatile stocks in US Market	2.9%

Estadísticas fundamentales de HSDT
Capitalización bursátil	US$134.22m
Beneficios(TTM)	-US$157.27m
Ingresos (TTM)	US$12.07m

Estadísticas clave de rentabilidad del último informe de resultados (TTM)
Cuenta de resultados (TTM) de HSDT
Ingresos	US$12.07m
Coste de los ingresos	US$540.00k
Beneficio bruto	US$11.53m
Otros gastos	US$168.81m
Beneficios	-US$157.27m

Beneficios por acción (BPA)	-2.60
Margen bruto	95.53%
Margen de beneficio neto	-1,302.80%
Ratio deuda/patrimonio	0%

Datos	Última actualización (huso horario UTC)
Análisis de la empresa	2026/09/14 17:05
Precio de las acciones al final del día	2026/09/11 00:00
Beneficios	2026/06/30
Ingresos anuales	2025/12/31

Paquete	Datos	Marco temporal	Ejemplo Fuente EE.UU. ^*
Finanzas de la empresa	10 años	Cuenta de resultados Estado de tesorería Balance	Formulario SEC 10-K Formulario SEC 10-Q
Estimaciones del consenso de analistas	+3 años	Previsiones financieras Objetivos de precios de los analistas	Informes de análisis Blue Matrix
Precios de mercado	30 años	Precios de las acciones Dividendos, escisiones y acciones	Datos de mercado ICE Formulario S-1 de la SEC
Propiedad	10 años	Accionistas principales Información privilegiada	Formulario SEC 4 Formulario SEC 13D
Gestión	10 años	Equipo directivo Consejo de Administración	Formulario SEC 10-K Formulario SEC DEF 14A
Principales avances	10 años	Anuncios de empresas	Formulario SEC 8-K

Solana (HSDT) Resumen de Acciones

Recompensas

Análisis de riesgos

Analyst Price Targets

Pacific Backbone And Tokenization Tailwinds Will Support A Stronger Long Term Outlook

On Chain Real World Assets And Asia Payments Will Reshape This Digital Asset Treasury

Staking And On Chain Yield Pressures Will Eventually Support A More Resilient Business Model

Top Analyst Narratives

Pacific Backbone And Tokenization Tailwinds Will Support A Stronger Long Term Outlook

On Chain Real World Assets And Asia Payments Will Reshape This Digital Asset Treasury

Staking And On Chain Yield Pressures Will Eventually Support A More Resilient Business Model

Competidores de Solana Company

Orchestra BioMed Holdings

QT Imaging Holdings

Lucid Diagnostics

Guided Therapeutics

Historial de precios y rendimiento

Noticias y actualizaciones recientes

HSDT: Cost Improvements And Alatau City Partnership Will Support Future Upside

HSDT: Cost Improvements Will Support Future Repricing Despite Lowered Fair Value Estimate

Solana Company to Report Q2, 2026 Results on Aug 14, 2026

Solana Partners With Alatau City to Build Central Asia Digital Asset Hub

HSDT: Bullish Initiations And Asia Pacific Partnership Will Support Long-Term Upside

Forward Industries, Inc. (NasdaqCM:FWDI) cancelled the acquisition of Solana Company (NasdaqCM:HSDT) for $98.3 million.

Recent updates

HSDT: Cost Improvements And Alatau City Partnership Will Support Future Upside

HSDT: Cost Improvements Will Support Future Repricing Despite Lowered Fair Value Estimate

Solana Company to Report Q2, 2026 Results on Aug 14, 2026

Solana Partners With Alatau City to Build Central Asia Digital Asset Hub

HSDT: Bullish Initiations And Asia Pacific Partnership Will Support Long-Term Upside

Forward Industries, Inc. (NasdaqCM:FWDI) cancelled the acquisition of Solana Company (NasdaqCM:HSDT) for $98.3 million.

New minor risk - Market cap size

Less than half of directors are independent

First quarter 2026 earnings: Revenues exceed analysts expectations while EPS lags behind

New major risk - Revenue and earnings growth

Solana Company to Report Q1, 2026 Results on May 15, 2026

Staking And On Chain Yield Pressures Will Eventually Support A More Resilient Business Model

Solana Company has completed a Follow-on Equity Offering in the amount of $7.999997 million.

Solana Company has filed a Follow-on Equity Offering in the amount of $7.999997 million.

Pacific Backbone And Tokenization Tailwinds Will Support A Stronger Long Term Outlook

Solana Company, Annual General Meeting, May 21, 2026

Solana Company Appoints Madelene Gani as Chief Operating Officer and Deputy Chief Financial Officer, Effective April 6, 2026

On Chain Real World Assets And Asia Payments Will Reshape This Digital Asset Treasury

Full year 2025 earnings released

Solana Company to Report Q4, 2025 Results on Mar 30, 2026

Solana Company and Alaska Digital and Kamino Launches the First-Ever Digital Asset Treasury to Enable Borrowing Against Natively Staked Sol in Qualified Custody

Solana (NASDAQ:HSDT) Is In A Good Position To Deliver On Growth Plans

Solana Company announced delayed 10-Q filing

High number of new directors

Helius Medical Technologies, Inc. Announces FDA 510(K) Submission for Pons Device Label Expansion in Stroke

Helius Medical Technologies, Inc. announced that it has received $433.113116 million in funding from a group of investors

Helius Medical Technologies, Inc. has filed a Follow-on Equity Offering in the amount of $92.8 million.

Insufficient new directors

Helius Medical Technologies, Inc. Announces Positive Outcome of the Portable Neuromodulation Stimulator PoNS®? Stroke Registrational Program and Upcoming Submission to FDA Under Breakthrough Designation

Helius Medical Technologies, Inc. Announces Claim Authorization by Cignahealth, for Its Portable Neuromodulation Stimulator (Pons®) Device

Helius Medical Technologies, Inc. Announces Positive PoNSTEP Study Results for PoNS Therapy

Helius Medical Technologies, Inc. Announces Authorized Claim for Payment by Major Healthcare Payer for its Portable Neuromodulation Stimulator (PoNS®) Device

Helius Medical Technologies, Inc. has filed a Follow-on Equity Offering.

Helius Medical Technologies, Inc. to Spotlight Study Confirming Improved Long-Term Outcomes from Adherence to PoNS Therapy®? at CMSC Annual Meeting

Helius Medical Technologies, Inc. Announces Reimbursement by Major Healthcare Provider for Its Portable Neuromodulation Stimulato Device

Helius Medical Technologies, Inc. announced a financing transaction

Nasdaq Grants Helius Medical Technologies an Extension, Until June 30, 2025 to Regain Compliance with the Minimum Bid Price Requirement as well as the Stockholders’ Equity Requirement

Helius Medical Technologies, Inc., Annual General Meeting, Apr 21, 2025

Helius Medical Technologies Provides Nasdaq Non-Compliance Update Regarding Minimum Bid Price Requirement

Helius Medical Technologies, Inc. Announces First Clinical Evidence of Positive Long-Term Therapeutic Effects of PoNS Therapy on Gait Deficit Improvement in Multiple Sclerosis from the PoNS Therapeutic Experience Program Study

Helius Medical Technologies, Inc. Announces Strong Enrollment of Its Stroke Pivotal Study Exceeding Initial Target

Helius Medical Technologies, Inc. Provides Updates on Efforts to Achieve Fair Market Access for Its Portable Neuromodulation Stimulator Device

Helius Medical Technologies, Inc. Announces Positive Preliminary Results of the PoNSTEP Study

Helius Medical Technologies Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Helius Medical Technologies, Inc. to Report Q2, 2024 Results on Aug 12, 2024

Helius Medical Technologies, Inc. Completes Site Participation Enrollment for Its U.S. Registrational Program in Stroke

Helius Medical Technologies, Inc., Annual General Meeting, Jun 27, 2024

Helius Medical Technologies, Inc. Announces Pons Is Now Available on the Veterans Affairs (VA) Federal Supply Schedule (FSS) and General Services Administration (GSA) Advantage Contracts

Helius Medical Technologies, Inc. to Report Q1, 2024 Results on May 13, 2024

Helius Medical Technologies, Inc. Expands Stroke Clinical Program with Participation of Shepherd Center

Helius Medical Technologies, Inc. has filed a Follow-on Equity Offering.

Helius Medical Technologies Receives Written Notice from the Nasdaq Stock Market

Helius Medical Technologies, Inc. to Report Q4, 2023 Results on Mar 28, 2024

Helius Medical Technologies, Inc. Initiates Open-Label Study for Registrational Program in Stroke

Helius Medical Technologies, Inc. Announces Alignment with FDA on Registrational Program for Treatment of Stroke Patients